Anesiva, Inc. (Nasdaq: ANSV) is a late-stage biopharmaceutical company focused on the development and commercialization of novel therapeutic treatments for pain management.
The company’s first product, Zingo™ (lidocaine hydrochloride monohydrate) powder intradermal injection system, was approved by the U.S. Food and Drug Administration (FDA) in August 2007 to reduce the pain associated with venous access procedures, such as IV insertions or blood draws, in children ages three to 18.
Anesiva and Particle Therapeutics have entered into an agreement granting us a licence to incorporate Anesiva’s drug delivery technology into our needle-free, transdermal delivery system for glucagon. For further details, please click here.
Oxford Centre for Diabetes, Endocrinology & Metabolism (OCDEM)
OCDEM is a pioneering centre which combines clinical care, research and education in diabetes, endocrine annd metabolic diseases. By promoting world-class research, it aims to enhance understanding of these diseases and to accelerate the search for new treatments and cures.
OCDEM will design our clinical trials for glucagon, which will be undertaken both at OCDEM in the UK, and at a site in the US.